Vivoryon Therapeutics N.V. (VVY.AS)
EUR 1.97
(0.71%)
EUR 1.97
(0.71%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -28.34 Million EUR | -0.66% |
| 2022 | -28.15 Million EUR | -122.49% |
| 2021 | -12.65 Million EUR | 23.35% |
| 2020 | -16.51 Million EUR | -111.04% |
| 2019 | -7.82 Million EUR | -1.11% |
| 2018 | -7.73 Million EUR | 3.4% |
| 2017 | -8 Million EUR | 42.34% |
| 2016 | -13.89 Million EUR | -2.86% |
| 2015 | -13.5 Million EUR | -18.08% |
| 2014 | -11.43 Million EUR | -15.19% |
| 2013 | -9.92 Million EUR | 46.96% |
| 2012 | -18.72 Million EUR | -14.8% |
| 2011 | -16.3 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -13.55 Million EUR | 0.0% |
| 2023 FY | -28.34 Million EUR | -0.66% |
| 2023 Q2 | -10.71 Million EUR | 0.0% |
| 2023 Q4 | -17.62 Million EUR | 0.0% |
| 2022 Q4 | -15.57 Million EUR | 0.0% |
| 2022 FY | -28.15 Million EUR | -122.49% |
| 2022 Q2 | -12.58 Million EUR | 0.0% |
| 2021 Q4 | -984 Thousand EUR | 0.0% |
| 2021 Q2 | -11.67 Million EUR | 0.0% |
| 2021 FY | -12.65 Million EUR | 23.35% |
| 2020 Q4 | -8.93 Million EUR | 0.0% |
| 2020 FY | -16.51 Million EUR | -111.04% |
| 2020 Q2 | -7.57 Million EUR | 0.0% |
| 2019 Q4 | -4.73 Million EUR | 0.0% |
| 2019 Q2 | -3.09 Million EUR | 0.0% |
| 2019 FY | -7.82 Million EUR | -1.11% |
| 2018 Q2 | -4.12 Million EUR | 0.0% |
| 2018 FY | -7.73 Million EUR | 3.4% |
| 2018 Q4 | -3.61 Million EUR | 0.0% |
| 2017 Q2 | -4.3 Million EUR | 0.0% |
| 2017 FY | -8 Million EUR | 42.34% |
| 2017 Q4 | -3.7 Million EUR | 0.0% |
| 2016 Q4 | -7.84 Million EUR | 0.0% |
| 2016 FY | -13.89 Million EUR | -2.86% |
| 2016 Q2 | -6.04 Million EUR | 0.0% |
| 2015 Q4 | -7.27 Million EUR | 0.0% |
| 2015 FY | -13.5 Million EUR | -18.08% |
| 2015 Q2 | -6.23 Million EUR | 0.0% |
| 2014 Q4 | -7.64 Million EUR | 0.0% |
| 2014 FY | -11.43 Million EUR | -15.19% |
| 2014 Q2 | -3.79 Million EUR | 0.0% |
| 2013 Q4 | -4.94 Million EUR | -100.28% |
| 2013 Q3 | -2.46 Million EUR | 48.73% |
| 2013 Q2 | -4.81 Million EUR | -95.06% |
| 2013 FY | -9.92 Million EUR | 46.96% |
| 2013 Q1 | -2.46 Million EUR | 0.0% |
| 2012 Q2 | -2.88 Million EUR | 0.0% |
| 2012 Q3 | -2.88 Million EUR | 0.0% |
| 2012 Q4 | -2.46 Million EUR | 14.37% |
| 2012 FY | -18.72 Million EUR | -14.8% |
| 2012 Q1 | -2.88 Million EUR | 0.0% |
| 2011 Q3 | -3.56 Million EUR | 0.0% |
| 2011 Q4 | -2.88 Million EUR | 19.13% |
| 2011 Q2 | -3.56 Million EUR | 0.0% |
| 2011 Q1 | -3.56 Million EUR | 0.0% |
| 2011 FY | -16.3 Million EUR | 0.0% |
| 2010 Q4 | -3.56 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -705.628% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 80.816% |
| Adocia SA | -21.16 Million EUR | -33.929% |
| Aelis Farma SA | -5.07 Million EUR | -458.133% |
| Biophytis S.A. | -17.02 Million EUR | -66.463% |
| Advicenne S.A. | -7.03 Million EUR | -303.101% |
| genOway Société anonyme | 1.56 Million EUR | 1908.016% |
| IntegraGen SA | -171.39 Thousand EUR | -16435.686% |
| Medesis Pharma S.A. | -3.95 Million EUR | -615.799% |
| Neovacs S.A. | -8.74 Million EUR | -224.151% |
| NFL Biosciences SA | -3.74 Million EUR | -656.7% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 35899.366% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -793.802% |
| Sensorion SA | -22.06 Million EUR | -28.457% |
| Theranexus Société Anonyme | -6.82 Million EUR | -315.088% |
| TME Pharma N.V. | -6.73 Million EUR | -320.754% |
| Valbiotis SA | -7.36 Million EUR | -284.663% |
| TheraVet SA | -1.57 Million EUR | -1704.41% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -39.314% |
| argenx SE | -272.91 Million EUR | 89.615% |
| BioSenic S.A. | -28.77 Million EUR | 1.515% |
| Celyad Oncology SA | -8.44 Million EUR | -235.488% |
| DBV Technologies S.A. | -67.26 Million EUR | 57.868% |
| Galapagos NV | 211.69 Million EUR | 113.388% |
| Genfit S.A. | -28.89 Million EUR | 1.91% |
| GeNeuro SA | -14.75 Million EUR | -92.058% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -84.278% |
| Innate Pharma S.A. | -7.57 Million EUR | -274.399% |
| Inventiva S.A. | -110.42 Million EUR | 74.334% |
| MaaT Pharma SA | -19.71 Million EUR | -43.744% |
| MedinCell S.A. | -25.03 Million EUR | -13.196% |
| Nanobiotix S.A. | -39.7 Million EUR | 28.61% |
| Onward Medical N.V. | -36.18 Million EUR | 21.666% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -745.287% |
| OSE Immunotherapeutics SA | -23 Million EUR | -23.21% |
| Oxurion NV | -18.96 Million EUR | -49.412% |
| Pharming Group N.V. | -9.75 Million EUR | -190.491% |
| Poxel S.A. | -35.09 Million EUR | 19.231% |
| GenSight Biologics S.A. | -26.22 Million EUR | -8.093% |
| Transgene SA | -22.32 Million EUR | -26.935% |
| Financière de Tubize SA | 88.15 Million EUR | 132.152% |
| UCB SA | 343 Million EUR | 108.263% |
| Valneva SE | -101.42 Million EUR | 72.057% |